Document is current
Any future updates will be listed below
-
Authors
Ronnacker, Julian https://orcid.org/0009-0006-1955-0709
Ruhnke, Leo
Röllig, Christoph https://orcid.org/0000-0002-3791-0548
Middeke, Jan Moritz
Herbst, Regina
Morgner, Anke https://orcid.org/0009-0004-2918-2554
Unglaub, Julia M.
Sauer, Tim
Huber, Karin
Baden, David https://orcid.org/0000-0002-4519-1002
Fransecky, Lars
Gezer, Melanie Nogueira
Crysandt, Martina
Jost, Edgar
Jentzsch, Madlen https://orcid.org/0000-0002-2270-0804
Metzeler, Klaus H. https://orcid.org/0000-0003-3920-7490
Berdel, Andrew F. https://orcid.org/0000-0002-7120-2780
Urbahn, Marc-André https://orcid.org/0009-0001-1019-5150
Kolloch, Lina https://orcid.org/0009-0001-4850-7359
Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Platzbecker, Uwe
Brümmendorf, Tim H.
Baldus, Claudia https://orcid.org/0000-0002-0748-834X
Müller-Tidow, Carsten https://orcid.org/0000-0002-7166-5232
Hänel, Mathias
Bornhäuser, Martin https://orcid.org/0000-0002-5916-3029
Wethmar, Klaus
Krug, Utz
Lenz, Georg
Mikesch, Jan-Henrik
Schliemann, Christoph https://orcid.org/0000-0003-1755-9583
- License Information
-
More Information
Article History
Received: 20 February 2025
Revised: 23 May 2025
Accepted: 19 June 2025
First Online: 3 July 2025
Competing interests
: CR received honoraria from AbbVie, Astellas, Bristol-Meyer-Squibb, Daiichi Sankyo, Jazz, Janssen, Novartis, Otsuka, Pfizer, Servier, and institutional research funding from AbbVie, Astellas, Novartis, Pfizer. JMM has served as a consultant for Janssen, Roche, Gilead, Abbvie, JAZZ Pharmaceuticals, Pfizer, Astellas, Novartis, AstraZeneca, Beigene, Glycostem; is a shareholder of Cancilico and Synagen; has received research funding from Servier, Janssen, and Novartis; has received travel support from Beigene. JMU received travel grants from Jazz Pharmaceuticals and AbbVie. TS received honoraria and travel support from Jazz Pharmaceuticals and is part of the advisory board of Jazz Pharmaceuticals. MJ received honoraria from Jazz Pharmaceuticals. AFB received speaker honoraria and travel grant from AbbVie. MH received honoraria from Novartis, Gilead, the Falk Foundation, SOBI, and BMS. MH is consultant for Janssen, Kite, Amgen, Sanofi, BMS, and BeiGene. MH received travel support from Abbvie. MS received grants not related to this manuscript from Pfizer. MS received honoraria not related to this manuscript from Pfizer, Jazz, Amgen, Novartis, Gilead, Celgene, medac, BMS, MSD, Incyte. MB received lecture fees and honoraria for advisory board participation from Jazz Pharmaceuticals and served on advisory boards for Acitrexx and MSD. GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. CS received institutional research support not related to this manuscript from Jazz Pharmaceuticals. CS received honoraria not related to this manuscript from AbbVie, Astellas, AstraZeneca, BMS, Laboratories Delbert, Jazz Pharmaceuticals, Novartis, Otsuka, Pfizer, Roche, and travel grants from AbbVie, BMS, Jazz Pharmaceuticals, Pfizer.
: All described methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from participants for inclusion in the clinical AML registry of the SAL (NCT03188874). The study was approved by the local Ethics Committee of Westphalia-Lippe (AZ 2023-032-f-S) as well as by the institutional review board of the SAL.
